Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheryl Ho

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 7, 2024
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trialJ Connor Wells, Monica M Mullin, Cheryl Ho, et al.
Clinical Lung Cancer|June 28, 2006
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancerAngela M Davies, Cheryl Ho, Primo N Lara, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung CancerKelly Li, Ian Bosdet, Stephen Yip, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|February 10, 2023
The perceptions and adoption of environmentally sustainable practices among anesthesiologists-a qualitative studyMa W W Zaw, Kah M Leong, Xiaohui Xin, et al.
Breast Cancer Research and Treatment|October 21, 2019
Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adultsHiten Naik, Bonnie Leung, Janessa Laskin, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic TherapyRebekah Rittberg, Bonnie Leung, Aria Shokoohi, et al.
Cancer Treatment and Research Communications|March 26, 2021
Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomasJulia R Naso, Norbert Banyi, Zamzam Al-Hashami, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologistsShaan Dudani, Natasha B Leighl, Cheryl Ho, et al.
The European Respiratory Journal|June 6, 2024
Surgically resectable nonsmall cell lung cancer: a contemporary approachMarie-Frédérique D'Amours, Florence T H Wu, Olivia Theisen-Lauk, et al.
Cancers|January 11, 2025
Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot StudyIan Janzen, Cheryl Ho, Barbara Melosky, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|March 7, 2024
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trialJ Connor Wells, Monica M Mullin, Cheryl Ho, et al.
Clinical Lung Cancer|June 28, 2006
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancerAngela M Davies, Cheryl Ho, Primo N Lara, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung CancerKelly Li, Ian Bosdet, Stephen Yip, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|February 10, 2023
The perceptions and adoption of environmentally sustainable practices among anesthesiologists-a qualitative studyMa W W Zaw, Kah M Leong, Xiaohui Xin, et al.
Breast Cancer Research and Treatment|October 21, 2019
Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adultsHiten Naik, Bonnie Leung, Janessa Laskin, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic TherapyRebekah Rittberg, Bonnie Leung, Aria Shokoohi, et al.
Cancer Treatment and Research Communications|March 26, 2021
Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomasJulia R Naso, Norbert Banyi, Zamzam Al-Hashami, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologistsShaan Dudani, Natasha B Leighl, Cheryl Ho, et al.
The European Respiratory Journal|June 6, 2024
Surgically resectable nonsmall cell lung cancer: a contemporary approachMarie-Frédérique D'Amours, Florence T H Wu, Olivia Theisen-Lauk, et al.
Cancers|January 11, 2025
Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot StudyIan Janzen, Cheryl Ho, Barbara Melosky, et al.
Pageof 12